GLENN H. RICHMOND; GRANT D. BEARDSLEY
Since the first clinical use of nitrogen mustard compounds in 1942,1 hundreds of articles have appeared in the medical literature to attest its value in the palliative therapy of Hodgkin's disease, lymphosarcoma, chronic leukemia and other neoplastic diseases. The narrow margin between the toxic and the therapeutic dose is shown by the occurrence of toxicity in almost every case treated effectively. It has been generally accepted that toxicity is a necessary accompaniment of effective therapy, and the literature on this subject has been limited. The pharmacologic activities of the nitrogen and sulfur mustards have been excellently presented by Gilman and
Learn more about subscription options.
Register Now for a free account.
RICHMOND GH, BEARDSLEY GD. NITROGEN MUSTARD THERAPY COMPLICATED BY ACUTE RENAL FAILURE DUE TO URIC ACID CRYSTALLIZATION(NITROGEN MUSTARD THERAPY COMPLICATED BY ACUTE RENAL FAILURE DUE TO URIC ACID CRYSTALLIZATION*). Ann Intern Med. 1953;39:1327–1332. doi: 10.7326/0003-4819-39-6-1327
Download citation file:
Published: Ann Intern Med. 1953;39(6):1327-1332.
Acute Kidney Injury, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only